Khan A, Lin P, Kamdar N, Peterson M, Mahmoudi E. Potentially preventable hospitalizations and use of preventive services among people with multiple sclerosis: large cohort study, USA. Mult Scler Relat Disord. 2022 Dec;68:104105. doi: 10.1016/j.msard.2022.104105
Kamudoni P, Amtmann D, Johns J, Cook KF, Salem R, Salek S, Raab J, Middleton R, Repovic P, Alschuler KN, von Geldern G, Wundes A, Barrett A, Olayinka-Amao B, Henke C. The validity, responsiveness, and score interpretation of the PROMISnq Physical Function - Multiple Sclerosis 15a short form in multiple sclerosis. Mult Scler Relat Disord. 2022 Jun;62:103753. doi: 10.1016/j.msard.2022.103753
Poudel N, Banjara B, Kamau S, Frost N, Ngorsuraches S. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis. Mult Scler Relat Disord. 2021 Feb;48:102720. doi: 10.1016/j.msard.2020.102720
Penner I-K, McDougall F, Brown TM, Slota C, Doward L, Julian L, Belachew S, Miller D. Exploring the impact of fatigue in progressive multiple sclerosis: a mixed-methods analysis. Mult Scler Relat Disord. 2020 Aug;43:102207. doi: 10.1016/j.msard.2020.102207
Quittner AL, Alpern AN, Wolin D, McLeod L, Downey C, Nelson L, Khandelwal N. Pysychometric analyses of a new GI symptom tracker for cystic fibrosis. Poster presented at the 31st Annual North American Cystic Fibrosis Conference; November 2, 2017. Indianapolis, IN. [abstract] Pediatr Pulmonol. 2017 Sep 19; 52(S47):S453. doi: 10.1002/ppul.23840
Quittner AL, Alpern AN, Wolin D, McLeod L, Downey C, Nelson L, Khandelwal N. Psychometric analyses of a new GI symptom tracker for cystic fibrosis. Poster presented at the 31st Annual North American Cystic Fibrosis Conference; September 19, 2017. Indianapolis, IN. [abstract] Pediatr Pulmonol. 52(S47):453.
Santanello N, Norquist J, Nelsen L, Williams V, Hill CD, Bisgaard H. Validation of a pediatric caregiver diary to measure symptoms of postacute respiratory syncytial virus bronchiolitis. Pediatr Pulmonol. 2005 Jul 1;40(1):31-8.
Enger C, Rothman KJ, Kylstra JW. Mortality rates during two years of treatment with intermittent inhaled tobramycin (TOBI) in cystic fibrosis. Pediatr Pulmonol. 1999 Sep 22;28(Suppl 19):339-40.